Clinical Trial Update: ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ravulizumab (ALXN1210) with eculizumab in adults with paroxysmal nocturnal hemoglobinuria who are already receiving eculizumab; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Eculizumab (Soliris) (eculizumab)
• Ravulizumab (ALXN1210) (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: COMPLETED | Results posted: 2019-03-21